Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -9 of 9 Show results per page	View Search Criteria \| Help With Results


1.		A Study of Tanespimycin (KOS-953) in Patients With Multiple Myeloma in First Relapse

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Pharmaceutical / Industry				CA200-004 KAG-301, NCT00546780

Last Modified: 8/27/2008 First Published: 7/23/2004


2.		Phase II Study of 17-N-Allylamino-17-Demethoxygeldanamycin in Patients With Von Hippel-Lindau Disease and Renal Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				NCI				NCI-04-C-0238 6399, NCI-6399, NCT00089375

Last Modified: 1/5/2009 First Published: 9/25/2004


3.		Phase II Study of Gemcitabine Hydrochloride and 17-N-Allylamino-17-Demethoxygeldanamycin (17-AAG) in Patients With Recurrent Advanced Ovarian Epithelial or Primary Peritoneal Cavity Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				NCI				MAYO-MC0362 6307, NCI-6307, NCT00093496

Last Modified: 11/20/2008 First Published: 6/25/2005


4.		Phase II Study of 17-N-Allylamino-17-Demethoxygeldanamycin (17-AAG) in Patients With Inoperable Locoregionally Advanced or Metastatic Medullary or Differentiated Thyroid Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				NCI				MAYO-MC0476 6482, NCI-6482, NCT00118248, JHOC-JS0652, JHOC-B/06/174

Last Modified: 5/8/2008 First Published: 6/25/2005


5.		Phase II Study of 17-N-Allylamino-17-Demethoxygeldanamycin (17-AAG) in Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Classical Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				Over 16				NCI				MDA-2004-0792 6936, NCI-6936, NCT00117988

Last Modified: 11/8/2008 First Published: 12/18/2007


6.		Phase II Randomized Study of Gemcitabine Hydrochloride and Tanespimycin (17-AAG) in Patients With Stage IV Pancreatic Adenocarcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Biomarker/Laboratory analysis, Treatment				Active				18 and over				NCI				MAYO-MC0542 MC0542, 7351, NCI-7351, NCT00577889

Last Modified: 12/3/2008 First Published: 5/1/1999


7.		Phase I Study of Geldanamycin Analogue (AAG) in Patients With Advanced Solid Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Active				19 and over				NCI				UNMC 170-04 MB-NAVY-98-10, NCI-T98-0075, NCI-99-C-0054, T98-0075, NCT00019708

Last Modified: 11/10/2008 First Published: 10/25/2004


8.		Phase I Study of 17-N-Allylamino-17-Demethoxygeldanamycin (17-AAG) and Bortezomib in Patients With Advanced Solid Tumors or Lymphomas

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Active				18 and over				NCI				MAYO-MC0214 6121, NCI-6121, NCT00096005

Last Modified: 9/19/2007 First Published: 11/22/2004


9.		Phase I Study of 17-N-allylamino-17-demethoxygeldanamycin (17-AAG) and Cytarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, or High-Grade Myelodysplastic Syndromes

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Active				18 and over				NCI				MAYO-MC0313 6383, NCI-6383, NCT00098423

Select All on One Page

| | | | | | | |

A Service of the National Cancer Institute